After-hours movers: CytomX jumps on Moderna deal, WWE gains as McMahon supports possible sale
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to After-hours movers: CytomX jumps on Moderna deal, WWE gains as McMahon supports possible sale
January 6, 2023 12:36 PM EST
Benchmark analyst Mike Hickey reiterated a Buy rating and $86.00 price target on World Wrestling Entertainment (NYSE: WWE) on news founder of WWE, Vince McMahon, will be returning to the Board and intends to undertake a review of its strategic alternatives with the... More
January 6, 2023 12:17 PM EST
Morgan Stanley analyst Matthew Harrison labeled Moderna (NASDAQ: MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock.
The analyst told investors the firm expects Moderna's first interim analysis from its Ph3 RSV vaccine study in the near term.
"We believe efficacy and... More
January 6, 2023 6:09 AM EST
Guggenheim on World Wrestling Entertainment (NYSE: WWE): 'We are designating WWE as our Best Idea'.
Analyst Curry Baker comments "Vince McMahon (founder, controlling shareholder of WWE) communicated to WWE's Board of Directors yesterday (link) that he would rejoin the Board as Executive Chairman... More
